Journal
Journal of virology
Publication Date
4-13-2022
Volume
96
Issue
7
First Page
e0005722
Document Type
Open Access Publication
DOI
10.1128/jvi.00057-22
Rights and Permissions
Xiang J, Lu M, Shi M, Cheng X, Kwakwa KA, Davis JL, Su X, Bakewell SJ, Zhang Y, Fontana F, Xu Y, Veis DJ, DiPersio JF, Ratner L, Sanderson RD, Noseda A, Mollah S, Li J, Weilbaecher KN. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. J Virol. 2022 Apr 13;96(7):e0005722. doi.org/10.1128/jvi.00057-22
Recommended Citation
Xiang, Jingyu; Lu, Mijia; Shi, Min; Cheng, Xiaogang; Kwakwa, Kristin A; Davis, Jennifer L; Su, Xinming; Bakewell, Suzanne J; Zhang, Yuexiu; Fontana, Francesca; Xu, Yalin; Veis, Deborah J; DiPersio, John F; Ratner, Lee; Sanderson, Ralph D; Noseda, Alessandro; Mollah, Shamim; Li, Jianrong; and Weilbaecher, Katherine N, "Heparanase blockade as a novel dual-targeting therapy for COVID-19." Journal of virology. 96, 7. e0005722 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11927
